About the Program:
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HIV infection.
Learning Objectives:
Upon completion of the program, participants should be able to:
- Provide increased prevention efforts to reduce the rate of HIV infection in African American women
- Initiate increased HIV testing rates in African American women
- Engage African American women with HIV in HIV care
- Evaluate and address barriers to provide optimal outcomes in African American women with HIV
Release Date: April 7, 2021
Expiration Date: April 7, 2022
Estimated time to complete each Module: 15 - 45 minutes
Media: Internet
Computer System Requirements: Internet Connection and Browser
Faculty:
Michelle Cespedes, MD
Associate Professor of Medicine, Division of Infectious Diseases
The Mount Sinai Hospital
New York, New York
Helena Kwakwa, MD, MPH
Director HIV Clinical Services
Philadelphia Department of Public Health
Ambulatory Health Services
Philadelphia, Pennsylvania
Wilbert Jordan, MD
Medical Director
OASIS Clinic of King/Drew Medical Center
Los Angeles, California
LaShonda Spencer, MD
Director
Drew Center for AIDS Research Education and Services
Charles Drew University of Medicine and Science
Los Angeles, California
Back to Top
Joint Accreditation Statement:
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Back to Top
Credit Designation:
Module 1 (Overview and Risk Assessment):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Testing and Linkage to Care):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (Engagement in HIV Care):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Evaluating and Addressing Barriers to Care):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5 (Discussion on HIV and COVID-19):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires faculty, planners and
others in
control of educational content to disclose all thier financial
relationships with ineligible companies. All identified conflicts of
interest (COI) are thoroughly vetted and mitigated
according to PIM policy. PIM is committed to providing its learners with
high quality accredited continuing education activities and related
materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the content of this
CME activity:
Michelle Cespedes, MD:
- Consulting Fees: Gilead, ViiV
|
Wilbert Jordan, MD:
- Consulting Fees: ViiV, Gilead
- Contracted Research: Gilead
|
Helena Kwakwa, MD:
- Contracted Research: ViiV
|
LaShonda Spencer, MD:
- Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their agents: Gilead
|
The PIM planners and others have nothing to disclose. The ViralEd, Inc. planners and others have nothing to disclose
Back to Top
Method of Participation and Request for Credit
1) Go to http://www.cmeuniversity.com/
2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the
email you entered is already in use", please click the Forgot my
Username or Password link to have your Username and Password sent to you
via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 15999 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) (If applicable) Complete the Post-test with a passing score of 75% or better
7) Complete the online Evaluation
8) Receive an immediate CE Certificate to download and/or print for your files
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
This activity is supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products, LP.
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
|